The continuous challenge of cardiovascular and bone disease in uremic patients: Clinical consequences of hyperphosphatemia and advanced therapeutic approaches

Journal of Nephrology

Volumn 19, Issue 1, 2006, Pages 12-20

  Brancaccio, Diego ^a   Zoccali, Carmine ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

Author keywords

Lanthanum carbonate; Phosphate binders; Sevelamer; Uremia

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM SALT; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SALT; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; SEVELAMER; VITAMIN D;

BIOACCUMULATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIALYSIS; DIET RESTRICTION; DISEASE COURSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BINDING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TISSUE LEVEL; HIGH RISK POPULATION; HORMONAL REGULATION; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER TOXICITY; MULTIPLE DRUG DOSE; NONHUMAN; OSTEOMALACIA; PARATHYROID HORMONE RELEASE; PATHOGENESIS; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PREDICTION; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; UREMIA;

BIOLOGICAL MARKERS; BONE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; PHOSPHATES; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; UREMIA;

EID: 33645471689     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
2. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002; 17 (suppl 11): S50-4.
3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (suppl): S16-23.
4. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 2003; (85): S105-10.
5. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-7.
6. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-8.
7. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17.
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18.
10. Kopple JD. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37 (suppl 2): S66-70.
11. National Kidney Foundation. K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 (suppl 3): S1-202.
12. Clinical algorithms on renal osteodystrophy. Nephrol Dial Transplant 2000; 15 (suppl 5): S39-57.
13. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-61.
14. Taylor JE, Henderson IS, Stewart WK, Mactier RA. Calcium carbonate 1250 mg/1260 mg: an affective phosphate binder. Scott Med J 1990; 35: 45-7.
15. Caravaca F, Santos I, Cubero JJ, Esparrago JF, Arrobas M, Pizarro JL, Robles R, Sanchez-Casado E. Calcium acetate versus calcium carbonate as phosphate binders in hemodialysis patients. Nephron 1992; 60: 423-7.
16. Emmet M, Sirmon MD, Kirkpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 17: 544-50.
17. Schaefer K, Scheer J, Asmus G, Umlauf E, Hagemann J, von Herrath D. The treatment of uraemic hyperphosphatemia with calcium acetate and calcium carbonate: a comparative study. Nephrol Dial Transplant 1991; 6: 170-5.
18. Choy BY, Lo WK, Cheng IK. Effectiveness of calcium acetate as phosphate binder in patients undergoing continuous ambulatory peritoneal dialysis. Hong Kong Med J 1998; 4: 23-6.
19. Janssen MJ, van der Kuy A, ter Wee PM, van Boven WP. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Clin Nephrol 1996; 45: 111-9.
20. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR. Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65: 1914-26.
21. Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminium levels after discontinuation of aluminium-containing gels in children receiving dialysis. J Pediatr 1986; 108: 767-70.
22. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus, Delmez J. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 1989; 36: 897-903.
23. Ittel TH, Schaefer C, Schmitt H, Gladziwa U, Sieberth HG. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia. Klin Wochenschr 1991; 69: 59-67.
24. Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kidney Dis 1987; 9: 206-10.
25. Malberti F, Surian M, Poggio F, Minoia C, Salvadeo A. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis 1988; 12: 487-91.
26. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003; 18 (suppl 3): S2-8.
27. Mai ML, Emmett M, Sheikh MS, Santa Ana CA, Schiller L, Fordtran JS. Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int 1989; 36: 690-5.
28. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elastoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-83.
29. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-21.
30. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 2005; 20: 764-72.
31. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt D, Goldberg D, Bonventre JV, Slatopolsky E. Poly [allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71.
32. Damment SJ, Webster I. The pharmacology of lanthanum carbonate (Fosrenol): a novel non-aluminium, non-calcium phosphate binder. Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, CA, 14-17 November 2003.
33. Pennick M, Damment SJ, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol) a novel non-aluminium, non-calcium phosphate binder. Poster presented at the 36th Annual Meeting of the American Society of Nephrology, San Diego, CA, 14-17 November 2003.
34. Lacour B, Lucas A, Auchèere D, Ruellan N, Mariaud de Serre Patey N, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-9.
35. Hutchison A. Analysis of liver function and hepatobiliary adverse event data from 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate. Abstract presented at the 42nd EDTA-ERA Meeting, Istanbul, 4-7 June 2005.
36. Joy MS, Finn WF; LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107.
37. Al-Baaj F, Speake M, Hutchison AJ. Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant 2005; 20: 775-82.
38. Finn WF, Joy MS, Hladik G; Lanthanum Study Group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004; 62: 193-201.
39. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol TM) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; (85): S73-8.
40. Hutchison A. Analysis of haematological data from over 2000 dialysis patients participating in clinical trials on the new phosphate binder, lanthanum carbonate. Poster presented at the 42nd EDTA-ERA Meeting, Istanbul, 4-7 June 2005.
41. Malluche HH, Freemont A, Denton J, Faugere MC, Wang G, Damment SJ, Webster I. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate for up to 5 years. Poster presented at the 37th Annual Meeting of the American Society of Nephrology, St Louis, MO, 29 October - 1 November 2004.